|
1
|
Rees M, Tekkis PP, Welsh FK, O'Rourke T
and John TG: Evaluation of long-term survival after hepatic
resection for metastatic colorectal cancer: A multifactorial model
of 929 patients. Ann Surg. 247:125–135. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
van der Pool AE, de Wilt JH, Lalmahomed
ZS, Eggermont AM, Ijzermans JN and Verhoef C: Optimizing the
outcome of surgery in patients with rectal cancer and synchronous
liver metastases. Br J Surg. 97:383–390. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Goéré D, Deshaies I, de Baere T, Boige V,
Malka D, Dumont F, Dromain C, Ducreux M and Elias D: Prolonged
survival of initially unresectable hepatic colorectal cancer
patients treated with hepatic arterial infusion of oxaliplatin
followed by radical surgery of metastases. Ann Surg. 251:686–691.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giacchetti S, Itzhaki M, Gruia G, Adam R,
Zidani R, Kunstlinger F, Brienza S, Alafaci E, Bertheault-Cvitkvoic
F, Jasmin C, et al: Long-term survival of patients with
unresectable colorectal cancer liver metastases following
infusional chemotherapy with 5-fluorouracil, leucovorin,
oxaliplatin and surgery. Ann Oncol. 10:663–669. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tanaka K, Adam R, Shimada H, Azoulay D,
Lévi F and Bismuth H: Role of neoadjuvant chemotherapy in the
treatment of multiple colorectal metastases to the liver. Br J
Surg. 90:963–969. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Adam R, Pascal G, Castaing D, Azoulay D,
Delvart V, Paule B, Levi F and Bismuth H: Tumor progression while
on chemotherapy: A contraindication to liver resection for multiple
colorectal metastases? Ann Surg. 240:1052–1064. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Johnston PG, Lenz HJ, Leichman CG,
Danenberg KD, Allegra CJ, Danenberg PV and Leichman L: Thymidylate
synthase gene and protein expression correlate and are associated
with response to 5-fluorouracil in human colorectal and gastric
tumors. Cancer Res. 55:1407–1412. 1995.PubMed/NCBI
|
|
8
|
Li S, Zhu L, Yao L, Xia L and Pan L:
Association between ERCC1 and TS mRNA levels and disease free
survival in colorectal cancer patients receiving oxaliplatin and
fluorouracil (5-FU) adjuvant chemotherapy. BMC Gastroenterol.
14:1542014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choueiri MB, Shen JP, Gross AM, Huang JK,
Ideker T and Fanta P: ERCC1 and TS expression as prognostic and
predictive biomarkers in metastatic colon cancer. PLoS One.
10:e01268982015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Noda E, Maeda K, Inoue T, Fukunaga S,
Nagahara H, Shibutani M, Amano R, Nakata B, Tanaka H, Muguruma K,
et al: Predictive value of expression of ERCC 1 and GST-p for
5-fluorouracil/oxaliplatin chemotherapy in advanced colorectal
cancer. Hepatogastroenterology. 59:130–133. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Geva R, Shamai S, Brazowsky E, Paoulas M,
Ben-Haim M, Johnstone E, Alex B and Shacham-Shmueli E: The
predictive role of ERCC1 status in oxaliplatin based neoadjuvant
therapy for metastatic colorectal cancer (mCRC) to the liver.
Cancer Invest. 33:89–97. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Han JJ, Baek SK, Lee JJ, Kim GY, Kim SY
and Lee SH: Combination of TRAP1 and ERCC1 expression predicts
clinical outcomes in metastatic colorectal cancer treated with
Oxaliplatin/5-fluorouracil. Cancer Res Treat. 46:55–64. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wolff AC, Hammond ME, Hicks DG, Dowsett M,
McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M,
Fitzgibbons P, et al: Recommendations for human epidermal growth
factor receptor 2 testing in breast cancer: American society of
clinical oncology/college of american pathologists clinical
practice guideline update. J Clin Oncol. 31:3997–4013. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Trillet-Lenoir V, Freyer G, Kaemmerlen P,
Fond A, Pellet O, Lombard-Bohas C, Gaudin JL, Lledo G, Mackiewicz
R, Gouttebel MC, et al: Assessment of tumour response to
chemotherapy for metastatic colorectal cancer: Accuracy of the
RECIST criteria. Br J Radiol. 75:903–908. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Japanese Society for Cancer of the Colon
and RectumGeneral Rules for Clinical and Pathological Studies on
Cancer of the Colon, Rectum and Anus. 7th edition. Tokyo: Japanese
Society for Cancer of the Colon and Rectum; 2006
|
|
17
|
Edge SB, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC cancer staging manual. 7th edition.
Springer NY; New York: 2010
|
|
18
|
Rubbia-Brandt L, Giostra E, Brezault C,
Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Manjo PE,
Soubrane O, et al: Importance of histological tumor response
assessment in predicting the outcome in patients with colorectal
liver metastases treated with neo-adjuvant chemotherapy followed by
liver surgery. Ann Oncol. 18:299–304. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dede K, Salamon F, Landherr L, Jakab F and
Bursics A: Pathologic assessment of response to chemotherapy in
colorectal cancer liver metastases after hepatic resection: which
method to use? Pathol Oncol Res. 21:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Noble F, Hopkins J, Curtis N, Kelly JJ,
Bailey IS, Byrne JP, Bateman AC, Bateman AR and Underwood TJ: The
role of systemic inflammatory and nutritional blood-borne markers
in predicting response to neoadjuvant chemotherapy and survival in
oesophagogastric cancer. Med Oncol. 30:5962013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fareed KR, Al-Attar A, Soomro IN, Kaye PV,
Patel J, Lobo DN, Parsons SL and Madhusudan S: Tumour regression
and ERCC1 nuclear protein expression predict clinical outcome in
patients with gastro-oesophageal cancer treated with neoadjuvant
chemotherapy. Br J Cancer. 102:1600–1607. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Valtorta E, Misale S, Sartore-Bianchi A,
Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs
B, Ercolani C, et al: KRAS gene amplification in colorectal cancer
and impact on response to EGFR-targeted therapy. Int J Cancer.
133:1259–1265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nishioka Y, Shindoh J, Yoshioka R, Gonoi
W, Abe H, Okura N, Yoshida S, Oba M, Hashimoto M, Watanabe G, et
al: Radiological morphology of colorectal liver metastases after
preoperative chemotherapy predicts tumor viability and
postoperative outcomes. J Gastrointest Surg. 19:1653–1661. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chun YS, Vauthey JN, Boonsirikamchai P,
Maru DM, Kopetz S, Palavecino M, Curley SA, Abdalla EK, Kaur H,
Charnsangavej C and Loyer EM: Association of computed tomography
morphologic criteria with pathologic response and survival in
patients treated with bevacizumab for colorectal liver metastases.
JAMA. 302:2338–2344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Van Triest B, Pinedo HM, Giaccone G and
Peters GJ: Downstream molecular determinants of response to
5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann
Oncol. 11:385–391. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bertino JR and Banerjee D: Is the
measurement of thymidylate synthase to determine suitability for
treatment with 5-fluoropyrimidines ready for prime time? Clin
Cancer Res. 9:1235–1239. 2003.PubMed/NCBI
|
|
27
|
Popat S, Matakidou A and Houlston RS:
Thymidylate synthase expression and prognosis in colorectal cancer:
A systematic review and meta-analysis. J Clin Oncol. 22:529–536.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leichman CG, Lenz HJ, Leichman L,
Danenberg K, Baranda J, Groshen S, Boswell W, Metzger R, Tan M and
Danenberg PV: Quantitation of intratumoral thymidylate synthase
expression predicts for disseminated colorectal cancer response and
resistance to protracted-infusion fluorouracil and weekly
leucovorin. J Clin Oncol. 15:3223–3229. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shirota Y, Stoehlmacher J, Brabender J,
Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg
PV and Lenz HJ: ERCC1 and thymidylate synthase mRNA levels predict
survival for colorectal cancer patients receiving combination
oxaliplatin and fluorouracil chemotherapy. J Clin Oncol.
19:4298–4304. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Silvestris N, Simone G, Partipilo G,
Scarpi E, Lorusso V, Brunetti AE, Maiello E, Paradiso A and Mangia
A: CES2, ABCG2, TS and Topo-I primary and synchronous metastasis
expression and clinical outcome in metastatic colorectal cancer
patients treated with first-line FOLFIRI regimen. Int J Mol Sci.
15:15767–15777. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Arienti C, Tesei A, Verdecchia GM,
Framarini M, Virzi S, Grassi A, Scarpi E, Turci L, Silverstrini R,
Amadori D and Zoli W: Role of conventional chemosensitivity test
and tissue biomarker expression in predicting response to treatment
of peritoneal carcinomatosis from colon cancer. Clin Colorectal
Cancer. 12:122–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Locker GY, Hamilton S, Harris J, Jessup
JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF and Bast RC Jr:
ASCO: ASCO 2006 update of recommendations for the use of tumor
markers in gastrointestinal cancer. J Clin Oncol. 24:5313–5327.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lim B, Mun J, Kim JH, Kim CW, Roh SA, Cho
DH, Kim YS and Kim JC: Genome-wide mutation profiles of colorectal
tumors and associated liver metastases at the exome and
transcriptome levels. Oncotarget. 6:22179–22190. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Baba H, Baba Y, Uemoto S, Yoshida K,
Saiura A, Watanabe M, Maehara Y, Oki E, Ikeda Y, Matsuda H, et al:
Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after
first-line chemotherapy of metastatic colorectal cancer: Results of
a multicenter study. Oncotarget. 6:34004–34013. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
López-Gómez M, Moreno-Rubio J,
Suárez-García I, Cejas P, Madero R, Casado E, Jiménez A, Sereno M,
Gómez-Raposo C, Zambrana F, et al: SMAD4 and TS expression might
predict the risk of recurrence after resection of colorectal liver
metastases. Clin Trans Oncol. 17:133–138. 2015. View Article : Google Scholar
|
|
36
|
Kumamoto K, Kuwabara K, Tajima Y, Amano K,
Hatano S, Ohsawa T, Okada N, Ishibashi K, Haga N and Ishida H:
Thymidylate synthase and thymidine phosphorylase mRNA expression in
primary lesions using laser capture microdissection is useful for
prediction of the efficacy of FOLFOX treatment in colorectal cancer
patients with liver metastasis. Oncol Lett. 3:983–989. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jones OM, Rees M, John TG, Bygrave S and
Plant G: Biopsy of resectable colorectal liver metastases causes
tumour dissemination and adversely affects survival after liver
resection. Br J Surg. 92:1165–1168. 2005. View Article : Google Scholar : PubMed/NCBI
|
